Skip to main content

Table 1 Baseline demographic and disease characteristics of ITT patient population

From: Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study

Characteristic

Result (n = 162)

Demographics

 

 Age, years

37.4 ± 9.8

Sex

 

 Male, n (%)

40 (24.7 %)

 Female, n (%)

122 (75.3 %)

Race

 

 Caucasian, n (%)

153 (94.4 %)

 Black, n (%)

2 (1.2 %)

 Asian, n (%)

2 (1.2 %)

 Other, n (%)

5 (3.1 %)

 Education, total years completed

14.9 ± 3.3

Disease characteristics

 

 MS classification

 

  Relapsing-remitting, n (%)

156 (96.3 %)

  Secondary progressive, n (%)

6 (3.7 %)

  Months since onset of MS symptoms

53.3 ± 76.1

  Months since MS diagnosis

24.0 ± 57.6

  Months since last relapse

6.4 ± 9.5

Number of relapses since onset of MS symptoms, n (%)

 

 0

6 (3.7 %)

 1

44 (27.2 %)

 2

55 (34.0 %)

 3

34 (21.0 %)

 4

12 (7.4 %)

 ≥5

11 (6.8 %)

 Expanded disability status scale (EDSS) Score

1.8 ± 1.3

Cognitive function

 

 Symbol digit modalities test (SDMT)

51.0 ± 13.1

 Patients failing test, n (%)

35 (22.9 %)

Selective reminding test (SRT)

 

 Long-term storage

41.8 ± 15.5

 Patients failing test, n (%)

61 (40.4 %)

 Consistent long-term retrieval

30.0 ± 15.8

 Patients failing test, n (%)

59 (39.1 %)

3-second paced auditory serial addition test (PASAT)

42.8 ± 11.4

 Patients failing test, n (%)

47 (31.3 %)

Cognitively impaired (failing ≥2 of the above tests)

67 (47.8 %)

  1. Data presented as mean ± standard deviation except as indicated
  2. ITT intent-to-treat, MS multiple sclerosis